Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: A Patient with Gout Develops Granulomatous Hepatitis

Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH  |  Issue: November 2019, October 2008  |  November 16, 2019

inflammatory agent during initiation to prevent these flares.

Also possible are numerous delayed hypersensitivity reactions, such as maculopapular exanthema, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms. Patients who are HLA-B*5801-genotype positive are at higher risk of developing these cutaneous reactions and should avoid allopurinol. This genotype is most often seen in patients of Korean, Han Chinese or Thai heritage.6

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Other adverse effects seen with allopurinol use include gastrointestinal upset (e.g., nausea, diarrhea), drowsiness, leukopenia and thrombocytopenia.6

Conclusion

Allopurinol-induced granulomatous hepatitis is a rare phenomenon that rheumatologists should be aware of given the frequency with which this drug is used. A discovery of this condition should prompt a change in therapy to another urate-lowering agent, such as febuxostat, which has not had any reported cases of granulomatous hepatitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This case serves as a reminder that any clinical presentation without a clear etiology warrants a review of the patient’s medication list. It is not possible to know every rare, adverse reaction to medications, but identifying a temporal relationship between a drug and a clinical presentation can help guide our clinical suspicions.  


Raj Vachhani, MD photoRaj Vachhani, MD, is a third-year postgraduate, studying internal medicine at the University of Alabama, Birmingham.

 

Angelo L. Gaffo, MD, MSPHAngelo L. Gaffo, MD, MSPH, is the rheuma­tology section chief at the Birmingham VA Medical Center and associate professor of medicine in the Division of Rheumatology at the University of Alabama, Birmingham.

 

References

  1. Lamps LW. Hepatic granulomas: A review with emphasis on infectious causes. Arch Pathol Lab Med. 2015 July;139(7):867–875.
  2. Zakim D, Boyer TD (Eds). Hepatology: A textbook of liver disease. Vol. 3. 3rd ed. Philadelphia: WB Saunders; 1996:1472.
  3. Culver EL, Watkins J, Westbrook RH. Granulomas of the liver. Clin Liver Dis (Hoboken). 2016 Apr 27;7(4):92–96.
  4. Simmons F, Feldman B, Gerety D. Granulomatous hepatitis in a patient receiving allopurinol. Gastroenterology. 1972 Jan;62(1):101–104.
  5. Iqbal U, Siddiqui HU, Anwar H, et al. Allopurinol-induced granulomatous hepatitis: A case report and review of literature. J Investig Med High Impact Case Rep. 2017 Sep 8;5(3):2324709617728302.
  6. Qurie A, Musa R. Allopurinol. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolgranulomatous hepatitis

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    The Granulomatosis of Wegener’s

    May 16, 2011

    Delving deeper into the nonvasculitis aspects of the disease

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences